Edgewise Shares Rise Premarket on FDA Fast-Track Designation
By Colin Kellaher
Edgewise Therapeutics shares moved higher in premarket trading Tuesday after the clinical-stage biopharmaceutical company won U.S. Food and Drug Administration fast-track designation for EDG-5506 for the treatment of Duchenne muscular dystrophy.
Shares, which closed Monday at $18.95, were recently up 7.9% to $20.45 in premarket trading.
The Boulder, Colo., company on Tuesday said it is currently conducting a pair of Phase 2 placebo-controlled studies of EDG-5506 in Duchenne, a severe, degenerative muscle disorder.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
The FDA previously granted orphan-drug designation to EDG-5506 for the treatment of Duchenne and Becker muscular dystrophy, rare-pediatric-disease designation for the treatment of Duchenne, and fast-track designation for the treatment of Becker.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 13, 2024 08:49 ET (13:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy